These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 29728940)
21. Immunotherapy in advanced anal cancer: Is the beginning of a new era? Ciardiello D; Guerrera LP; Maiorano BA; Parente P; Latiano TP; Di Maio M; Ciardiello F; Troiani T; Martinelli E; Maiello E Cancer Treat Rev; 2022 Apr; 105():102373. PubMed ID: 35279535 [TBL] [Abstract][Full Text] [Related]
22. Nonplatinum-based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population-based Danish anal cancer group study. Truelsen CG; Serup-Hansen E; Storm KS; Havelund BM; Kronborg CS; Spindler KG Cancer Med; 2021 May; 10(10):3224-3230. PubMed ID: 33960701 [TBL] [Abstract][Full Text] [Related]
23. Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma. Gordeyev SS; Rasulov AO; Gorbounova VA; Tkachev SI; Glebovskaya VV; Fedyanin MY; Besova NS; Surayeva YE Cancer Chemother Pharmacol; 2017 Sep; 80(3):623-629. PubMed ID: 28766008 [TBL] [Abstract][Full Text] [Related]
24. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Glynne-Jones R; Meadows H; Wan S; Gollins S; Leslie M; Levine E; McDonald AC; Myint S; Samuel L; Sebag-Montefiore D; Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):119-26. PubMed ID: 18472366 [TBL] [Abstract][Full Text] [Related]
25. Progress in the treatment of anal cancer: an overview of the latest investigational drugs. Yu J; Kim RD Expert Opin Investig Drugs; 2024 Feb; 33(2):145-157. PubMed ID: 38275174 [TBL] [Abstract][Full Text] [Related]
26. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Kim R; Byer J; Fulp WJ; Mahipal A; Dinwoodie W; Shibata D Oncology; 2014; 87(2):125-32. PubMed ID: 25012155 [TBL] [Abstract][Full Text] [Related]
27. Perspectives in Head and Neck Medical Oncology. Amanam I; Gupta R; Mita A; Scher K; Massarelli E Cancer Treat Res; 2018; 174():163-185. PubMed ID: 29435842 [TBL] [Abstract][Full Text] [Related]
30. HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report. Cabel L; Bidard FC; Servois V; Cacheux W; Mariani P; Romano E; Minsat M; Bieche I; Farkhondeh F; Jeannot E; Buecher B Int J Cancer; 2017 Oct; 141(8):1667-1670. PubMed ID: 28670746 [TBL] [Abstract][Full Text] [Related]
32. Treatment of the Primary Tumor in Anal Canal Cancers. Glynne-Jones R; Rao S Surg Oncol Clin N Am; 2017 Jan; 26(1):73-90. PubMed ID: 27889038 [TBL] [Abstract][Full Text] [Related]
33. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet; 1996 Oct; 348(9034):1049-54. PubMed ID: 8874455 [TBL] [Abstract][Full Text] [Related]
34. Current treatment for localized anal carcinoma. Das P; Crane CH; Ajani JA Curr Opin Oncol; 2007 Jul; 19(4):396-400. PubMed ID: 17545807 [TBL] [Abstract][Full Text] [Related]
36. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225 [TBL] [Abstract][Full Text] [Related]
37. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Matzinger O; Roelofsen F; Mineur L; Koswig S; Van Der Steen-Banasik EM; Van Houtte P; Haustermans K; Radosevic-Jelic L; Mueller RP; Maingon P; Collette L; Bosset JF; Eur J Cancer; 2009 Nov; 45(16):2782-91. PubMed ID: 19643599 [TBL] [Abstract][Full Text] [Related]
38. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Phan LK; Hoff PM Dis Colon Rectum; 2007 Mar; 50(3):395-8. PubMed ID: 17252287 [TBL] [Abstract][Full Text] [Related]
39. Optimizing outcomes of chemoradiation in the management of squamous cell carcinoma of the anal canal. McHaffie DR; Kozak KR Oncology (Williston Park); 2010 Apr; 24(5):424-7. PubMed ID: 20480741 [No Abstract] [Full Text] [Related]
40. [Rationale and progress of the phase III trial: intensification of the treatment of locally advanced squamous cell carcinoma of the anal canal]. Peiffert D Cancer Radiother; 2003 Nov; 7 Suppl 1():100s-107s. PubMed ID: 15124551 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]